IIA
CLDX icon

IPG Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

IPG Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,333
Closed -$72.2K – 141
2017
Q1 		$72.2K Buy
+1,333
New +$69.4K 0.03% 129

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IPG Investment Advisors's CLDX Position: Q2 2017 in Review

IPG Investment Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 1,333 shares — an estimated $72.2K sold.

IPG Investment Advisors first reported a position in CLDX in Q1 2017 and held it in 1 quarter. The position peaked at $72.2K in Q1 2017. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • IPG Investment Advisors reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • IPG Investment Advisors sold 1,333 Celldex Therapeutics shares in Q2 2017, an estimated $72.2K.
  • IPG Investment Advisors first reported a position in Celldex Therapeutics in Q1 2017 and held it in 1 quarter.
  • IPG Investment Advisors's Celldex Therapeutics position peaked at $72.2K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on IPG Investment Advisors's 13F filing for Q2 2017, filed 28 Jul 2017.